MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2021.05.045

Медицинская библиотека · JACC. Cardiovascular interventions · 2021

1-Year Results From a Prospective Experience on CAS Using the CGuard Stent System: The IRONGUARD 2 Study.

Sirignano Pasqualino, Stabile Eugenio, Mansour Wassim, Capoccia Laura, Faccenna Federico, Intrieri Francesco, Ferri Michelangelo, Saccà Salvatore, Sponza Massimo, Mortola Paolo, Ronchey Sonia, Praquin Barbara, Grillo Placido, Chiappa Roberto, Losa Sergio, Setacci Francesco, Pirrelli Stefano, Taurino Maurizio, Ruffino Maria Antonella, Udini Marco, Palombo Domenico, Ippoliti Arnaldo, Montelione Nunzio, Setacci Carlo, de Donato Gianmarco, Ruggeri Massimo, Speziale Francesco

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

The aim of this study was to evaluate the 1-year safety and efficacy of a dual-layered stent (DLS) for carotid artery stenting (CAS) in a multicenter registry.

BACKGROUND

DLS have been proved to be safe and efficient during short-term follow-up. Recent data have raised the concern that the benefit of CAS performed with using a DLS may be hampered by a higher restenosis rate at 1 year.

METHODS

From January 2017 to June 2019, a physician-initiated, prospective, multispecialty registry enrolled 733 consecutive patients undergoing CAS using the CGuard embolic prevention system at 20 centers. The primary endpoint was the occurrence of death and stroke at 1 year. Secondary endpoints were 1-year rates of transient ischemic attack, acute myocardial infarction, internal carotid artery (ICA) restenosis, in-stent thrombosis, and external carotid artery occlusion.

RESULTS

At 1 year, follow-up was available in 726 patients (99.04%). Beyond 30 days postprocedure, 1 minor stroke (0.13%), four transient ischemic attacks (0.55%), 2 fatal acute myocardial infarctions (0.27%), and 6 noncardiac deaths (1.10%) occurred. On duplex ultrasound examination, ICA restenosis was found in 6 patients (0.82%): 2 total occlusions and 4 in-stent restenoses. No predictors of target ICA restenosis and/or occlusion could be detected, and dual-antiplatelet therapy duration (90 days vs 30 days) was not found to be related to major adverse cardiovascular event or restenosis occurrence.

CONCLUSIONS

This real-world registry suggests that DLS use in clinical practice is safe and associated with minimal occurrence of adverse neurologic events up to 12-month follow-up.

Для цитирования: Sirignano Pasqualino, Stabile Eugenio, Mansour Wassim, Capoccia Laura, Faccenna Federico, Intrieri Francesco, Ferri Michelangelo, Saccà Salvatore, Sponza Massimo, Mortola Paolo, Ronchey Sonia, Praquin Barbara, Grillo Placido, Chiappa Roberto, Losa Sergio, Setacci Francesco, Pirrelli Stefano, Taurino Maurizio, Ruffino Maria Antonella, Udini Marco, Palombo Domenico, Ippoliti Arnaldo, Montelione Nunzio, Setacci Carlo, de Donato Gianmarco, Ruggeri Massimo, Speziale Francesco. 1-Year Results From a Prospective Experience on CAS Using the CGuard Stent System: The IRONGUARD 2 Study.. JACC. Cardiovascular interventions. 2021. DOI: 10.1016/j.jcin.2021.05.045.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.